We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Self-Swab Kit for COVID-19 Test Granted Emergency Use Authorization by FDA

By LabMedica International staff writers
Posted on 27 Nov 2020
Print article
A kit that allows individuals to collect their own nasal swabs and ship the specimens to a lab for COVID-19 testing has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

The COVID-19 self-testing kit was used by researchers at Stanford Medicine (Stanford, CA, USA) in the Community Alliance to Test Coronavirus at Home (CATCH) Study that aimed to better understand the demographics of COVID-19 infection, as well as to determine if at-home sample-collection kits could boost access to accurate testing. The Vera COVID-19 Unsupervised Collection Kit was developed by Stanford University and the Chan Zuckerberg Biohub. The test kits provide organizations with a cost-effective approach to testing individuals swiftly, reliably and securely for COVID-19.

The CATCH Study also utilized the Vera Cloud Testing Platform, a COVID-19 testing and tracking tool that Stanford Medicine is using to provide testing services to multiple organizations. With the kit, individuals can self-collect a sample using a safe and gentle nasal swab in the front their nostrils. The samples are returned to the Stanford Health Care Virology Laboratory by courier or FedEx, where they are tested for SARS-CoV-2, the coronavirus that causes COVID-19. The COVID-19 self-testing kit and Vera Cloud Testing Platform are also designed to be able to integrate with other labs and organizations for broader public health monitoring.

Data from a pilot study, which involved 43 adults across a wide spectrum of age, race, ethnicity and education, showed that self-collection was reliable and easy for all participants. Every participant was able to successfully collect a sample. An EUA allows experimental treatments and tests to be used outside of research studies. With the EUA, the self-collection kit provides another tool to broaden the availability of COVID-19 testing. The self-testing kit can now be disseminated broadly to organizations, businesses and individuals, as long as samples can be returned to the Stanford Virology Laboratory, or other participating laboratories, within 48 hours. The kit can help organizations outside Stanford Medicine, such as nursing homes, companies and colleges, reliably test for the presence of SARS-CoV-2, said Patrick Arensdorf, who is director of the CATCH study.

“This emergency-use authorization creates another avenue for testing that is less resource-intensive and doesn’t require a health care worker to observe or help,” said Christina Kong, MD, vice chair of clinical affairs and medical director of Stanford Health Care’s pathology and clinical laboratories.

Related Links:
Stanford Medicine

Print article


Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more


view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more


view channel

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.